Cargando…

UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study

BACKGROUND: Uridine diphosphate glucuronosyltransferase 1 family polypeptide A1 (UGT1A1) is a predictive biomarker for the side-effects of irinotecan chemotherapy, which reduces the volume of tumors harboring UGT1A1 polymorphisms. We aimed to determine whether UGT1A1 polymorphisms can predict progre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsuoka, Hideki, Murakami, Ryusuke, Abiko, Kaoru, Yamaguchi, Ken, Horie, Akihito, Hamanishi, Junzo, Baba, Tsukasa, Mandai, Masaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405427/ https://www.ncbi.nlm.nih.gov/pubmed/32758288 http://dx.doi.org/10.1186/s12885-020-07225-1

Ejemplares similares

The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients
por: So, Makiko, et al.
Publicado: (2019)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Low-Grade Endometrial Stromal Sarcoma with a Nodule-in-Nodule Appearance in Preoperative Magnetic Resonance Images
por: Nakamura, Mitsuhiro, et al.
Publicado: (2020)

Corrigendum to “Low-Grade Endometrial Stromal Sarcoma with a Nodule-in-Nodule Appearance in Preoperative Magnetic Resonance Images”
por: Nakamura, Mitsuhiro, et al.
Publicado: (2021)

PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma
por: Kitamura, Sachiko, et al.
Publicado: (2021)

Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics
por: Konishi, Ikuo, et al.
Publicado: (2022)

Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma
por: Inoue, Ayami, et al.
Publicado: (2017)

Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer
por: Abou-Taleb, Hisham A, et al.
Publicado: (2016)

Acquisition of a side population fraction augments malignant phenotype in ovarian cancer
por: Yamanoi, Koji, et al.
Publicado: (2019)

Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer
por: Murakami, Ryusuke, et al.
Publicado: (2021)

Metabolic alterations caused by HNF1β expression in ovarian clear cell carcinoma contribute to cell survival
por: Amano, Yasuaki, et al.
Publicado: (2015)

Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment
por: Horikawa, Naoki, et al.
Publicado: (2020)

Tertiary lymphoid structures are associated with favorable survival outcomes in patients with endometrial cancer
por: Qin, Meng, et al.
Publicado: (2021)

Clinical approaches to treating papillary squamous cell carcinoma of the uterine cervix
por: Nagura, Michikazu, et al.
Publicado: (2014)

Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients
por: Horikawa, Naoki, et al.
Publicado: (2015)

Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
por: Ohsuga, Takuma, et al.
Publicado: (2017)

Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation
por: Taki, Mana, et al.
Publicado: (2018)

Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer
por: Yamanoi, Koji, et al.
Publicado: (2016)

Placenta Accreta in a Woman with Childhood Uterine Irradiation: A Case Report and Literature Review
por: Sasagasako, Nanayo, et al.
Publicado: (2019)

Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma
por: Abou-Taleb, Hisham, et al.
Publicado: (2016)

Investigation of the Effect of Puncture Order and Position on the Difficulty of Lower and Middle Abdominal Port Placement
por: Nakai, Chihiro, et al.
Publicado: (2023)

VISTA expressed in tumour cells regulates T cell function
por: Mulati, Kumuluzi, et al.
Publicado: (2018)

B7-H3 Suppresses Antitumor Immunity via the CCL2–CCR2–M2 Macrophage Axis and Contributes to Ovarian Cancer Progression
por: Miyamoto, Taito, et al.
Publicado: (2022)

Invasive Paget's disease of the vulva treated with a combination of surgery and concurrent chemoradiotherapy: A case report
por: Inayama, Yoshihide, et al.
Publicado: (2018)

UGT1A1 polymorphisms in cancer: impact on irinotecan treatment
por: Takano, Masashi, et al.
Publicado: (2017)

Groin lymph node detection and sentinel lymph node biopsy in vulvar cancer
por: Sakae, Chieko, et al.
Publicado: (2016)

Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma
por: Yamaguchi, Ken, et al.
Publicado: (2021)

UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan
por: Kimura, Kei, et al.
Publicado: (2018)

Recurrence of a carcinoid tumor of the ovary 13 years after the primary surgery: A case report
por: AMANO, YASUAKI, et al.
Publicado: (2013)

Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy
por: Koshiyama, Masafumi, et al.
Publicado: (2017)

Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy
por: Liu, Xing-Han, et al.
Publicado: (2017)

The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan
por: Su, Y.-Y., et al.
Publicado: (2022)

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1
por: de With, Mirjam, et al.
Publicado: (2023)

Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan‐related toxicities in patients with lung cancer
por: Fukuda, Minoru, et al.
Publicado: (2017)

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
por: Abiko, K, et al.
Publicado: (2015)

Impact of UGT1A1 genotype on the efficacy and safety of irinotecan‐based chemotherapy in metastatic colorectal cancer
por: Iwasa, Satoru, et al.
Publicado: (2021)

Feasibility of Laparoscopic Para-Aortic Lymphadenectomy for Locally Advanced Cervical Cancer
por: Horikawa, Naoki, et al.
Publicado: (2022)

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
por: Marcuello, E, et al.
Publicado: (2004)

Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer
por: Fujii, Hironori, et al.
Publicado: (2018)

Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI
por: Lee, Lawrence Soon-U, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9vgl9fcl3e0ia3t30av13663d4